Provision Language
4. OBLIGATIONS OF MPP
[…]
4.2. Reports. During the period that MPP’s Sublicensees are developing the Products, MPP will provide Pfizer with an annual report describing (a) the status of development of each Product in development by each Sublicensee if applicable, (b) the regulatory filing plan with the WHO Pre-qualification Programme and/or a Stringent Regulatory Authority anticipated for each Product in the upcoming calendar year, and (c) a list of countries for which regulatory approvals or authorizations have been obtained during the reporting period for any Product. Such annual report shall be provided to Pfizer within ninety (90) days of the anniversary of the effective date of any Sublicense. Following regulatory approval for any Product by the WHO Pre-qualification Programme and/or a Stringent Regulatory Authority, MPP will send to Pfizer within 60 days following the end of each anniversary of the Effective Date a written report setting forth a list of countries for which regulatory approvals or authorizations have been obtained during the reporting period for any Product. Pfizer agrees that information contained in these annual and quarterly reports shall be treated as Confidential Information of MPP and its Sublicensee(s).
4.3 Notification of Material Breach. If MPP becomes aware of any act or omission of a Sublicensee which constitutes a breach of the relevant Sublicense MPP shall provide Pfizer with prompt notification and (i) if the breach is capable of correction and does not give rise to an immediate right of termination under the Sublicense, direct the relevant Sublicensee in writing to cure the breach; and (ii) if the breach remains uncured at the end of the specified period, or if there are otherwise grounds for termination under the Sublicense, terminate the relevant Sublicense in accordance with its terms.